Possible Biomarkers for Alzheimer's Disease

Ferris, Mary Elina
February 2011
Internal Medicine Alert;2/28/2011, Vol. 33 Issue 4, p29
The article presents an abstract and commentary of the of the study "Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline," by K. Yaffe and colleagues, which shows the association of lower plasma levels of beta-amyloid with greater cognitive decline in elderly persons.


Related Articles

  • Relationship between Memory Performance and β-Amyloid Deposition at Different Stages of Alzheimer's Disease. Chételat, Gaël; Villemagne, Victor L.; Pike, Kerryn E.; Ellis, Kathryn A.; Ames, David; Masters, Colin L.; Rowe, Christopher C. // Neurodegenerative Diseases;Apr2012, Vol. 10 Issue 1-4, p141 

    Background: Postmortem studies have suggested that β-amyloid (Aβ) deposition was only weakly related to the degree of cognitive impairment in Alzheimer's disease (AD). The development of Aβ ligands for in vivo PET imaging has greatly facilitated the assessment of this question....

  • Age-dependent postoperative cognitive impairment and Alzheimer-related neuropathology in mice. Zhipeng Xu; Yuanlin Dong; Hui Wang; Culley, Deborah J.; Marcantonio, Edward R.; Crosby, Gregory; Tanzi, Rudolph E.; Yiying Zhang; Zhongcong Xie // Scientific Reports;1/24/2014, p1 

    Post-operative cognitive dysfunction (POCD) is associated with increased cost of care, morbidity, and mortality. However, its pathogenesis remains largely to be determined. Specifically, it is unknown why elderly patients are more likely to develop POCD and whether POCD is dependent on general...

  • Amyloid-Related Memory Decline in Preclinical Alzheimer’s Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months. Thai, Christine; Lim, Yen Ying; Villemagne, Victor L.; Laws, Simon M.; Ames, David; Ellis, Kathryn A.; Rainey-Smith, Stephanie R.; Martins, Ralph N.; Masters, Colin L.; Rowe, Christopher C.; Maruff, Paul; null, null // PLoS ONE;10/2/2015, Vol. 10 Issue 10, p1 

    High levels of β-amyloid (Aβ) in the brain and carriage of the APOE ε4 allele have each been linked to cognitive impairment in cognitively normal (CN) older adults. However, the relationship between these two biomarkers and cognitive decline is unclear. The aim of this study was to...

  • Gene mutation defends against Alzheimer's disease. Callaway, Ewen // Nature;7/12/2012, Vol. 487 Issue 7406, p153 

    The article focuses on the role of gene mutation in the treatment of Alzheimer's disease. It relates the research by T. Jonsson which shows that people with genetic mutation can prevent the development of the disease and suggests that it is an extreme form of the cognitive decline in older...

  • MIND & MEMORY NEWSBRIEFS.  // DukeMedicine HealthNews;Jun2013, Vol. 19 Issue 6, p6 

    The article reports that the development that takes beta amyloid plaques in the brain is about 15 years and seeking treatment following the plaque accumulation can be a long treatment window when medications may able to slow cognitive decline.

  • Plasma β-Amyloid Level, Cognitive Reserve, and Cognitive Decline. Okereke, Olivia I.; Selkoe, Dennis J.; Grodstein, Francine; Pomara, Nunzio; Bruno, Davide; Sidtis, John J.; Yaffe, Kristine; Weston, Andrea // JAMA: Journal of the American Medical Association;4/27/2011, Vol. 305 Issue 16, p1655 

    Two letters to the editor are presented in response to the article "Association of Plasma β-Amyloid Level and Cognitive Reserve With Subsequent Cognitive Decline," by K. Yaffe and colleagues which was published in a 2011 issue.

  • Current therapeutic strategy in Alzheimer's disease. SINGH, S.; KUSHWAH, A. S.; SINGH, R.; FARSWAN, M.; KAUR, R. // European Review for Medical & Pharmacological Sciences;2012, Vol. 16 Issue 12, p1651 

    Alzheimer's disease (AD) is a chronic, progressive, neurodegenerative disorder that places a substantial burden on patients, their families, and society. Alzheimer's disease (AD) is the sixth leading cause of all deaths in the United States, and the fifth leading cause of death in Americans aged...

  • In Vivo Human Amyloid Imaging. Sojkova, J.; Resnick, S. M. // Current Alzheimer Research;Jul2011, Vol. 8 Issue 4, p366 

    PET imaging agents such as Pittsburgh compound B (PiB) allow detection of fibrillar �-amyloid (A�) in vivo. In addition to quantification of A� deposition in mild cognitive impairment and Alzheimer's disease, PiB has also increased our understanding of A� deposition in older...

  • Asymptomatic Alzheimer's Disease: A Prodrome or a State of Resilience? Driscoll, I.; Troncoso, J. // Current Alzheimer Research;Jul2011, Vol. 8 Issue 4, p330 

    Neuritic plaques and neurofibrillary tangles, the neuropathological hallmarks of AD, are not limited to individuals with dementia. These pathologic changes can also be present in the brains of cognitively normal older adults -- a condition we defined as Asymptomatic AD (ASYMAD). Although it...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics